Trials / Unknown
UnknownNCT04097080
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Nobilis Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease. The study will test the hypothesis that the gas mixture with xenon has a symptomatic treatment potential for patients with Parkinson's Disease, as measured by change from baseline in the Unified Parkinson Disease Rating Scale (UPDRS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NBTX-001 | Active drug group will receive 6 doses of NBTX-001 given three times a week. |
| DRUG | Standard of Care | Placebo group will receive reconstituted air given three times a week. |
Timeline
- Start date
- 2019-12-15
- Primary completion
- 2021-11-01
- Completion
- 2021-12-01
- First posted
- 2019-09-20
- Last updated
- 2021-03-03
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT04097080. Inclusion in this directory is not an endorsement.